tetano
Editor, Senior Moderator
Sci Transl Med
. 2022 Jul 12;eabo6160.
doi: 10.1126/scitranslmed.abo6160. Online ahead of print.
A bivalent SARS-CoV-2 monoclonal antibody combination does not impact the immunogenicity of a vector-based COVID-19 vaccine in macaques
Joseph P Nkolola[SUP] 1 [/SUP], Jingyou Yu[SUP] 1 [/SUP], Huahua Wan[SUP] 1 [/SUP], Aiquan Chang[SUP] 1 [/SUP], Katherine McMahan[SUP] 1 [/SUP], Tochi Anioke[SUP] 1 [/SUP], Catherine Jacob-Dolan[SUP] 1 [/SUP], Olivia Powers[SUP] 1 [/SUP], Tianyi Ye[SUP] 1 [/SUP], Abishek Chandrashekar[SUP] 1 [/SUP], Daniel Sellers[SUP] 1 [/SUP], Julia Barrett[SUP] 1 [/SUP], Yueh-Ming Loo[SUP] 2 [/SUP], Mark T Esser[SUP] 2 [/SUP], Robert H Carnahan[SUP] 3 4 [/SUP], James E Crowe Jr[SUP] 3 4 5 [/SUP], Dan H Barouch[SUP] 1 6 [/SUP]
Affiliations
Abstract
Human monoclonal antibodies (mAbs) that target the spike glycoprotein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) offer a promising approach for the prevention and treatment of coronavirus disease 2019 (COVID-19). Given suboptimal global vaccination rates, waning immunity in vaccinated individuals, and the emergence of SARS-CoV-2 variants of concern, the use of mAbs for COVID-19 prevention may increase and may need to be administered together with vaccines in certain settings. However, it is unknown whether administration of mAbs will impact the immunogenicity of SARS-CoV-2 vaccines. Using an adenovirus vector-based SARS-CoV-2 vaccine, we show that simultaneous administration of the vaccine with SARS-CoV-2 mAbs does not diminish vaccine-induced humoral or cellular immunity in cynomolgus macaques. These results suggest that SARS-CoV-2 mAbs and viral vector-based SARS-CoV-2 vaccines can be administered together without loss of potency of either product. Additional studies will be required to evaluate co-administration of mAbs with other vaccine platforms.
. 2022 Jul 12;eabo6160.
doi: 10.1126/scitranslmed.abo6160. Online ahead of print.
A bivalent SARS-CoV-2 monoclonal antibody combination does not impact the immunogenicity of a vector-based COVID-19 vaccine in macaques
Joseph P Nkolola[SUP] 1 [/SUP], Jingyou Yu[SUP] 1 [/SUP], Huahua Wan[SUP] 1 [/SUP], Aiquan Chang[SUP] 1 [/SUP], Katherine McMahan[SUP] 1 [/SUP], Tochi Anioke[SUP] 1 [/SUP], Catherine Jacob-Dolan[SUP] 1 [/SUP], Olivia Powers[SUP] 1 [/SUP], Tianyi Ye[SUP] 1 [/SUP], Abishek Chandrashekar[SUP] 1 [/SUP], Daniel Sellers[SUP] 1 [/SUP], Julia Barrett[SUP] 1 [/SUP], Yueh-Ming Loo[SUP] 2 [/SUP], Mark T Esser[SUP] 2 [/SUP], Robert H Carnahan[SUP] 3 4 [/SUP], James E Crowe Jr[SUP] 3 4 5 [/SUP], Dan H Barouch[SUP] 1 6 [/SUP]
Affiliations
- PMID: 35857623
- DOI: 10.1126/scitranslmed.abo6160
Abstract
Human monoclonal antibodies (mAbs) that target the spike glycoprotein of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) offer a promising approach for the prevention and treatment of coronavirus disease 2019 (COVID-19). Given suboptimal global vaccination rates, waning immunity in vaccinated individuals, and the emergence of SARS-CoV-2 variants of concern, the use of mAbs for COVID-19 prevention may increase and may need to be administered together with vaccines in certain settings. However, it is unknown whether administration of mAbs will impact the immunogenicity of SARS-CoV-2 vaccines. Using an adenovirus vector-based SARS-CoV-2 vaccine, we show that simultaneous administration of the vaccine with SARS-CoV-2 mAbs does not diminish vaccine-induced humoral or cellular immunity in cynomolgus macaques. These results suggest that SARS-CoV-2 mAbs and viral vector-based SARS-CoV-2 vaccines can be administered together without loss of potency of either product. Additional studies will be required to evaluate co-administration of mAbs with other vaccine platforms.